Evidence map›Paper›PMID 27903154›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.

Gadi Shlomai, Brian Neel, Derek LeRoith, Emily Jane Gallagher

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 136 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 11 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05132244 narecruitingnot on this mapstarted 2024, after this paper: background citation

Pancreatic Cancer Glucose Assessment and Regulation Study

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2024 to 2027Enrolled50ConditionsPancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, HyperglycemiaArmsEndocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM), Standard Care
NCT06299800 unknown statusnot on this mapstarted 2024, after this paper: background citation

Type 2 Diabetes Mellitus and Cancer: Phenotyping of Patients at a Third-level Diabetes Centre

TypeobservationalSponsorAzienda Ospedaliero Universitaria Maggiore della CaritaRan2024 to 2025Enrolled779ConditionsDiabetes Mellitus, Type 2, CancerArmsphenotyping of patients followed at a third-level diabetes centre with cancer
3 · Its place in the literature

Who cites it

136 citing papers in PubMed, 11 syntheses or guidelines pooled it, 240 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2017
    Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Association ofBioscience reports · 2019
    Trial
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

76 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gadi ShlomaiGadi Shlomai, Brian Neel, Derek LeRoith, and Emily Jane Gallagher, Icahn School of Medicine at Mount Sinai, New York, NY; and Gadi Shlomai, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Brian NeelGadi Shlomai, Brian Neel, Derek LeRoith, and Emily Jane Gallagher, Icahn School of Medicine at Mount Sinai, New York, NY; and Gadi Shlomai, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Derek LeRoithGadi Shlomai, Brian Neel, Derek LeRoith, and Emily Jane Gallagher, Icahn School of Medicine at Mount Sinai, New York, NY; and Gadi Shlomai, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Emily Jane GallagherGadi Shlomai, Brian Neel, Derek LeRoith, and Emily Jane Gallagher, Icahn School of Medicine at Mount Sinai, New York, NY; and Gadi Shlomai, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Icahn School of Medicine at Mount Sinai · US

Funding

Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancerR01CA128799 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEROITH, DEREK · 2008 to 2018
$3.7M
Insulin Resistance and Breast Cancer Prognosis in Black & White WomenR01CA171558 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BICKELL, NINA A., LEROITH, DEREK · 2012 to 2017
$3.1M
Obesity and triple negative breast cancer; the role of hypercholesterolemiaR01CA200553 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEROITH, DEREK · 2016 to 2020
$1.9M
Cholesterol promotes breast cancer progression: establishing the mechanismsK08CA190770 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GALLAGHER, EMILY JANE · 2014 to 2018
$843k
NCI NIH HHS K08 CA190770NCI NIH HHS R01 CA128799NCI NIH HHS R01 CA171558NCI NIH HHS R01 CA200553
6 · The paper itself

Abstract

Purpose Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide. Epidemiologic data suggest that T2DM is associated with an increased incidence and mortality from many cancers. The purpose of this review is to discuss the links between diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortality, and the effects of anticancer therapies on diabetes. Design This study is a review of preclinical and clinical data regarding the effects of antidiabetic medications on cancer incidence and mortality and the effects of anticancer therapies on glucose homeostasis. Results T2DM is associated with an increased risk and greater mortality from many cancer types. Metformin use has been associated with a decrease in cancer incidence and mortality, and there are many ongoing randomized trials investigating the effects of metformin on cancer-related outcomes. However, data regarding the association of other antidiabetes medications with cancer incidence and mortality are conflicting. Glucocorticoids, hormone-based therapies, inhibitors that target the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy have been associated with high rates of hyperglycemia. These agents mediate their deleterious metabolic effects by reducing insulin secretion and increasing insulin resistance in peripheral tissues. Conclusion Studies must be performed to optimize cancer screening strategies in individuals with T2DM. A greater understanding of the mechanisms that link diabetes and cancer are needed to identify targets for therapy in individuals with diabetes who develop cancer. Data from clinical studies are needed to further elucidate the effects of antidiabetic medications on cancer incidence and progression. As several anticancer therapies alter glucose homeostasis, physicians need to be aware of these potential effects. Careful patient screening and monitoring during treatment with these agents is necessary.

Indexed as

Antineoplastic AgentsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsIncidenceInsulin ResistanceNeoplasmsRisk FactorsAntineoplastic AgentsHypoglycemic Agents

Identifiers

PMID27903154
PMCPMC5455318
OpenAlexW2551488436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.